FdaApplication
BLA 103772
Identifiers
- fda_app_no: BLA103772
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 1998-08-24 |
Revenue by product
REMICADE
| Period | Revenue |
|---|---|
| Q2 2026 | $338.0M |
| Q1 2026 | $422.0M |
| Q4 2025 | $370.0M |
| Q3 2025 | $476.0M |
| Q2 2025 | $455.0M |
| Q1 2025 | $467.0M |
| Q4 2024 | $359.0M |
| Q3 2024 | $419.0M |
| Q2 2024 | $393.0M |
| Q1 2024 | $434.0M |
| Q4 2023 | $429.0M |
| Q3 2023 | $461.0M |
| Q2 2023 | $462.0M |
| Q1 2023 | $487.0M |
| Q4 2022 | $475.0M |
| Q3 2022 | $558.0M |
| Q2 2022 | $647.0M |
| Q1 2022 | $663.0M |
| Q4 2021 | $764.0M |
| Q3 2021 | $761.0M |
| Q2 2021 | $888.0M |
| Q1 2021 | $777.0M |
| Q4 2020 | $901.0M |
| Q3 2020 | $921.0M |
| Q2 2020 | $935.0M |
| Q1 2020 | $990.0M |
| Q4 2019 | $1.0B |
| Q3 2019 | $1.1B |
| Q2 2019 | $1.1B |
| Q1 2019 | $1.1B |
| Q4 2018 | $1.2B |
| Q3 2018 | $1.4B |
| Q2 2018 | $1.3B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| REMICADE | INFLIXIMAB | 100MG | For Injection |
1 product